Needham & Company Downgrades Argos Therapeutics (ARGS) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures tepid as Middle East tensions keep investors wary
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Tesla to unveil Cybercab Texas today, details are few
- Snowflake soars 20% on earnings beat and raised guidance
- Oil prices hit fresh 6-week highs on renewed Middle East tensions
JMP Securities Downgrades Argos Therapeutics (ARGS) to Market Perform
February 22, 2017 1:54 PM ESTJMP Securities downgraded Argos Therapeutics (NASDAQ: ARGS) from Market Outperform to Market Perform (from $12.00).
For an analyst ratings summary and ratings history on Argos Therapeutics click here. For more ratings news on Argos Therapeutics click here.
Shares of Argos Therapeutics closed at $4.40 yesterday.
... MoreFBR Capital Downgrades Argos Therapeutics (ARGS) to Market Perform
February 22, 2017 1:53 PM ESTFBR Capital downgraded Argos Therapeutics (NASDAQ: ARGS) from Outperform to Market Perform with a price target of $2.00 (from $13.00).
For an analyst ratings summary and ratings history on Argos Therapeutics click here. For more ratings news on Argos Therapeutics click here.
Shares of Argos Therapeutics closed at $4.40 yesterday.
... MoreStifel Downgrades Argos Therapeutics (ARGS) to Hold
February 22, 2017 11:00 AM ESTStifel downgraded Argos Therapeutics (NASDAQ: ARGS) from Buy to Hold with a price target of $1.40.
For an analyst ratings summary and ratings history on Argos Therapeutics click here. For more ratings news on Argos Therapeutics click here.
Shares of Argos Therapeutics closed at $4.40 yesterday.
... More